Notice of Allowability	Application No.	Applicant(s)	
	10/684,137	MATYJASZEWSKI	FT AI
	Examiner	Art Unit	
	Roberto Rábago	1713	
The MAILING DATE of this communication apper All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communicatio IGHTS. This application is subject	oplication. If not include in will be mailed in due	ed course. THIS
1. This communication is responsive to <u>6/26/2007</u> .			
2. The allowed claim(s) is/are <u>1-16,18-30 and 32-44</u> .			
<ul> <li>3. ☐ Acknowledgment is made of a claim for foreign priority una) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have</li> <li>2. ☐ Certified copies of the priority documents have</li> <li>3. ☐ Copies of the certified copies of the priority documents.</li> </ul>	e been received. e been received in Application No	<del></del>	king forms Abo
<ol> <li>Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ol>			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a reply IENT of this application.	complying with the rec	quirements
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.			
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached			
1) 🗌 hereto or 2) 🗋 to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1, each sheet. Replacement sheet(s) should be labeled as such in the	.84(c)) should be written on the draw he header according to 37 CFR 1.121	ings in the front (not the (d).	back) of
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s)  1. ☑ Notice of References Cited (DTC 200)	5 <b></b>		
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Dotice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>	5. Notice of Informal I		
	6. ☐ Interview Summary Paper No./Mail Da 7. ☑ Examiner's Amend		
<ol> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date</li> </ol>	7. 🛛 Examiner's Amend	ment/Comment	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	<ul><li>8. ☑ Examiner's Statem</li><li>9. ☐ Other</li></ul>	ent of Reasons for Allo	wance

#### **DETAILED ACTION**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Joseph Kent on 8/30/2007.

## In the specification:

In paragraph [0002], line 3, after "2003" insert --, now abandoned, --.

In paragraph [0008], line 4, after "09/972,046" insert --, now Pat. 6,627,314 --.

In paragraph [0008], line 4, after "09/972,260" insert --, now Pat. 6,624,262 --.

In paragraph [0008], line 4, after "10/625,890" insert --, now abandoned, --.

In paragraph [0008], line 4, after "10/034,908" insert --, now Pat. 7,049,373, --.

In paragraph [0008], line 5, after "10/271,025" insert --, now Pat. 6,759,491, --.

In paragraph [0079], line 15, after "09/972,260" insert --, now Pat. 6,624,262 --.

In paragraph [00110], line 2, after "09/018,554" insert --, now Pat. 6,538,091, --.

In paragraph [00110], line 3, after "09/369,157" insert --, now Pat. 6,541,580 --.

On page 64, line 6, delete "(which will be presented next month)".

Application/Control Number: 10/684,137 Page 3

Art Unit: 1713

# In the claims:

Cancel claims 31, 46 and 47.

In claim 1, line 7, change "10%" to -- "13%" --.

In claim 1, line 7, after "of" insert -- acidic monomers of --

In claim 5, line 2, delete "at a pH of" and change "90% of" to -- 90% at --.

In claim 9, change the dependency from claim 7 to claim 8.

In claim 14, change "an" to -- a --.

In claim 21, delete "a" and insert in its place -- an additional -- .

In claim 27, change the dependency from claim 26 to claim 18.

In claim 32, line 8, change "10%" to -- "13%" --.

In claim 32, line 8, after "of" insert -- acidic monomers of --.

#### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/26/2007 has been entered.

### Reasons for Allowance

Art Unit: 1713

3. The following is an examiner's statement of reasons for allowance. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

The claims are allowed in view of amendment requiring a minimum conversion of acidic monomers of at least 13%. Support for this value exists in the working examples wherein methacrylic acid is polymerized to conversions far exceeding 13%; since these polymerizations would necessarily pass through the claimed value of acidic monomer conversion, sufficient support exists for the newly claimed value. Applicants have shown in Comparative Example 4 that when using ligands of the type recommended in Matyjaszewski '937, conversion would not be expected to reach 13% (see Table 6). Furthermore, copolymerization of methyl methacrylate with methacrylic acid as shown in Example 6 of US 2004/0171779 attains only 11.8% conversion, and the reference includes no teaching of how to improve upon such low acidic monomer conversion.

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roberto Rábago whose telephone number is (571) 272-1109. The examiner can normally be reached on Monday - Friday from 8:00 - 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu can be reached on (571) 272-1114. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/684,137

Art Unit: 1713

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Roberto Rábago Primary Examiner Art Unit 1713

RR September 1, 2007